These two high-yield dividend stocks are trading at bargain-basement prices.
High-yield dividend stocks can be a great way to protect your portfolio from market volatility. Stocks that pay yields of 4% or higher can soften the blow from marketwide downturns through their elevated quarterly distributions. These types of equities also tend to hold up better in moody markets. Income investors, after all, rarely exit top-notch dividend plays because of the long-term nature of this particular strategy.
Which high-yield stocks are the most compelling buys right now? From a fundamental standpoint, legacy car manufacturer Ford Motor Company (F 0.66%) and the Japanese pharma giant Takeda Pharmaceutical (TAK -0.33%) both look exceptionally cheap right now. Read on to find out more about these two high-yield dividend stocks.
Ford
Ford, and most of its contemporaries, took a big step backward last year over concerns about the impact of rising interest rates on demand for new vehicles. The company’s shares, in fact, lost a staggering 44% of their value in 2022.
The direct consequence of Ford’s plummeting share price is that its annualized dividend yield ballooned to a whopping 4.97%. The carmaker’s shares are also trading at an eye-catching 65% discount, relative to Morningstar’s latest fair-value estimate of $20 per share, following this beeline move lower.
Can Ford close this latent valuation gap? There is a good chance this top auto manufacturer can regain its footing in 2023. A few tailwinds support this assertion.
First off, the anticipated drop in demand for vehicles in the U.S. and abroad failed to materialize over the course of 2022. Demand remains strong, despite hot inflation and rising interest rates.
Second, Ford is in the midst of a multipronged reorganization. The plan centers on improving operational efficiency, investing $50 billion into electric vehicle development, and streamlining international product offerings.
Although these strategic moves will take time to bear fruit, the auto giant appears to be headed in the right direction. Income investors, in turn, may want to take advantage of this sharp correction in Ford’s stock.
Takeda Pharmaceutical
Japanese drugmaker Takeda Pharmaceutical had a solid 2022. Thanks to its ongoing deleveraging effort, the strong organic growth of key products like ulcerative colitis medicine Entyvio and hereditary angioedema drug Takhzyro, and its noteworthy 4.29% annualized yield, Takeda’s shares posted a stellar 14.4% gain in 2022. Even so, Takeda’s stock is still only trading at a meager 11.4 times forward earnings.
Why isn’t Takeda’s stock garnering a higher multiple? The core reason it has failed to earn even an average premium, when most top-shelf pharma stocks trade at more than 15 times forward earnings, is that investors aren’t entirely sure what to make of the company’s long-term growth plan. The Japanese pharma titan is staring down key patent expirations for ADHD medication Vyvanse this year and another one for Entyvio in 2026. Moreover, its recent business development moves in autoimmune disease and cancer probably won’t contribute to earnings in a positive manner anytime soon.
What’s the bottom line? Takeda stock sports a highly attractive yield and valuation at current levels. However, the company will have to execute on multiple fronts to blunt the impact of aging medicines on its top and bottom lines in the years ahead. As a result, this inexpensive high-yield dividend stock does have some important risk factors to consider before buying it as a passive-income vehicle.
Read Next – Gold is about to SOAR – here’s what to do
As you read this, everything is lining up perfectly for a historic gold bull run.
- Gold recently climbed past $1,800/oz…
- Market uncertainty is high, with inflation worries causing many investors to scramble for safe havens…
- There’s no clear consensus on what the Fed will do to rates in 2023…
- And many commodity experts are raising their price target for gold.
Bottom line: NOW is the time you want to own gold!
Our research leads us to believe that we could see gold reach as high as $3,000 by the end of 2023… possibly higher.
Which makes why we’re reaching out to you today all the more urgent.
You see, we just put together a special presentation about our No. 1 pick for this current gold bull run.
It has more potential upside and substantially less risk than ANY other gold strategy we’ve ever seen…
In the past, folks investing in this same gold strategy could have been able to make nearly 50X their initial investment!
And today, you can take advantage of a similar situation for less than $10.
We’ve put together a detailed presentation (free) to show you exactly how this strategy works… and why it could lead to some of the biggest gains you’ll ever see from gold.
Considering how quickly the price of gold can move, you don’t want to waste any time missing out on the potential profits that I now see directly in front of us.
You can get all the details today right here.
